On this page
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system in which inflammation, demyelination, and neuroaxonal injury can produce neurologic symptoms that vary by lesion location and over time. A symptom or MRI finding alone does not establish MS. The NICE guideline for MS in adults, updated in June 2026, covers diagnosis using the revised McDonald criteria, coordinated care, symptom management, relapse, and disease-modifying treatment.
Quick reference
| Topic | Condition-specific guidance |
|---|---|
| Systems affected | Brain, spinal cord, and optic nerves |
| Clinical course | May be relapsing, progressive, or show both inflammatory activity and progression over time |
| Diagnosis | Neurologist-led integration of history, examination, MRI, and laboratory findings while excluding better explanations |
| Symptom change | Infection, heat, fatigue, medication effects, relapse, and progression can produce different patterns and require different responses |
| Communication | Speech, voice, language, cognition, vision, hearing, motor access, and fatigue should be assessed separately |
| Treatment | Disease-modifying and symptom treatment depend on disease course, activity, risks, preferences, and current needs |
Recognition and diagnosis
Presentations can include optic neuritis, altered sensation, weakness, impaired balance or coordination, double vision, bladder symptoms, fatigue, or other focal neurologic changes. Many of these symptoms have more common causes. Suspected MS should be assessed by a neurologist rather than diagnosed from symptoms, a scan, or a laboratory result in isolation.
Current NICE guidance directs clinicians to combine history, examination, MRI, and laboratory findings using the revised McDonald criteria. Cerebrospinal fluid or other tests may contribute in the appropriate clinical context, and alternative inflammatory, infectious, vascular, metabolic, structural, genetic, and functional explanations should be considered. If criteria are not met but suspicion remains, a review plan and clear contact instructions are appropriate (NICE recommendations).
Course, relapse, and urgent boundaries
MS may initially have relapses followed by improvement, may worsen gradually from onset, or may acquire progressive features after a relapsing course. Disease activity and progression are assessed over time; a person's current function cannot be predicted from a course label alone.
NICE defines a relapse as new or worsened neurologic symptoms lasting more than a day, after a stable period of about a month, when infection or another cause does not better explain them. This definition supports clinician assessment rather than self-treatment. The MS team should be contacted promptly about a possible relapse, particularly when usual activities are affected. Steroids are not appropriate for every relapse and should be decided with a clinician experienced in MS.
Sudden facial droop, one-sided weakness, severe new headache, acute confusion, collapse, new inability to swallow, or breathing difficulty needs emergency assessment because stroke and other emergencies can resemble an MS change. Fever, urinary or respiratory symptoms, or a rapid global decline also warrants prompt medical review. A pre-agreed plan should state whom to contact when symptoms change significantly.
Coordinated treatment and rehabilitation
Disease-modifying therapy is selected with an MS specialist according to clinical course, inflammatory activity, prior treatment, pregnancy plans, comorbidities, monitoring needs, risks, and preferences. Rehabilitation and symptom care may involve an MS nurse, neurology, rehabilitation medicine, physical and occupational therapy, speech-language pathology, psychology or neuropsychology, nutrition, continence services, social care, and primary care.
Comprehensive review should consider mobility and falls, fatigue, pain and sensation, spasticity, vision, bladder and bowel function, sleep, mood, cognition, speech, swallowing, respiratory function, medicines, work, relationships, and participation. New symptoms should not be attributed automatically to MS.
Speech, communication, and cognition
MS may affect speech precision, rate, rhythm, voice, breath support, word retrieval, processing speed, attention, memory, or executive function. Performance may fluctuate with fatigue, heat, pain, mood, sleep, vision, medication effects, and time of day. Assessment should document the person's best and difficult conditions rather than interpret inconsistency as poor effort.
Communication support may include reducing competing demands, allowing processing time, confirming key information, scheduling demanding conversations when energy is better, and using written or visual summaries in an accessible format. Cognitive concerns warrant review of reversible contributors and, when they affect daily life, functional assessment by an appropriately experienced clinician.
Swallowing and nutrition
Possible dysphagia signs include coughing or choking, wet or changed voice, food or pills sticking, prolonged meals, difficulty coordinating breathing and swallowing, weight loss, dehydration, or recurrent chest illness. Symptoms may vary with fatigue or relapse. Clinical assessment and, when indicated, instrumental evaluation should guide decisions about posture, pacing, texture, medication form, assistance, or nutrition. A diagnosis of MS alone does not determine a safe diet.
AAC and access planning
AAC can support communication during fatigue, relapse, noisy settings, or more persistent speech or language change. It is based on functional need, not on an MS subtype or anticipated stage. Preserve effective speech, gesture, writing, and partner strategies while considering low-tech and technology-supported options.
Access trials should account for tremor, weakness, sensation, coordination, vision, cognition, positioning, endurance, and day-to-day fluctuation. Touch, keyboards, voice input, switches, eye tracking, or partner-assisted scanning are possible methods to evaluate rather than default choices. The plan should include partner training, a low-effort backup, and a way to communicate during an acute change. See the AAC assessment and acquisition guide and ASHA AAC Practice Portal.
Prognosis and follow-up
The course of MS varies substantially. Prognostic discussion should distinguish group-level associations from the individual's disease activity, progression, symptoms, response to treatment, comorbidities, environment, and goals. Follow-up should revisit communication, swallowing, cognition, access, and participation after relapse, a sustained functional change, treatment change, or transition in living or work circumstances.